secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071386
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD
--------------------------------------------------------------------------------

- Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.
- Successful End-of-Phase 2 FDA meeting; alignment on Phase 3 design for CLS-AX targeting 3-6 month flexible dosing in wet AMD.
- Partner Arctic Vision: ARCATUS approved in Australia and Singapore; NDA accepted for review in China for uveitic macular edema.
- Partner BioCryst authorized to start clinical trial for avoralstat in DME using Clearside's SCS Microinjector; initial data expected in 2025.
- Cash $13.6M at March 31, expected to fund operations into Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025071386/0000950170-25-071386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025071386/clsd-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer